SLC5A2 and Hypertension: Statin therapy (QI-5), SGLT2 inhibitors and GLP-1RAs (QI-4), and the multiple drug therapy in hypertension (QI-2) were the cardiovascular pharmacotherapy with the most opportunities for intervention, due to alarmingly low adherence with these level A evidence clinical recommendations.